Pharma BD Deal Intelligence

Celgene Corporation / Forma Therapeutics Holdings, LLC

2014 · Co-Development · $600M · Complete

Announcement Sentiment

Strongly positive

Celgene paid Forma $225M upfront for a 3.5-year option-to-license arrangement on Forma's protein-homeostasis oncology pipeline. The deal was strategically notable as one of the largest preclinical option deals of 2014 and presaged the broader degrader/molecular-glue wave.

Key facts

Announced Mar 25, 2014
Closed Mar 25, 2014
Deal value $600M
Deal type Co-Development
Therapeutic area Hematologic malignancies and solid tumors
Indications Hematologic malignancies and solid tumors
Key assets Protein homeostasis-targeted oncology candidates
Mechanism Modulation of protein homeostasis (E3 ligases, chaperones, deubiquitinases)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals